Invention Grant
- Patent Title: (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
-
Application No.: US15497556Application Date: 2017-04-26
-
Publication No.: US10214477B2Publication Date: 2019-02-26
- Inventor: Alberto Ortega Muñoz , Matthew Colin Thor Fyfe , Marc Martinell Pedemonte , Maria de los Àngeles Estiarte Martinez , Nuria Valls Vidal , Guido Kurz , Julio Cesar Castro Palomino Laria
- Applicant: Oryzon Genomics S.A.
- Applicant Address: ES Madrid
- Assignee: Oryzon Genomics S.A.
- Current Assignee: Oryzon Genomics S.A.
- Current Assignee Address: ES Madrid
- Agency: Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
- Priority: EP11382324 20111020; EP11382329 20111027
- Main IPC: C07C211/36
- IPC: C07C211/36 ; C07D213/74 ; C07C271/24 ; C07C275/26 ; C07D231/12 ; C07D207/14 ; C07D277/28 ; C07D295/096 ; C07D295/135 ; C07D295/26 ; C07D213/30 ; C07D213/38 ; C07D307/52 ; C07C311/08 ; C07C311/21 ; C07C215/46 ; C07C217/54 ; C07C209/28 ; C07C211/38 ; C07C269/00 ; C07C273/18 ; C07C211/40 ; C07C213/00 ; C07C215/64 ; C07C217/74 ; C07C273/00 ; C07D213/57 ; C07D213/73 ; C07D231/56 ; C07D333/20
Abstract:
The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.
Public/Granted literature
- US20180079709A1 (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS Public/Granted day:2018-03-22
Information query
